Table 2.
Means (SD) for FACT-G/FACT-M subscales, by sample cohort (N = 41)
| FACT-G
|
FACT-M | |||||
|---|---|---|---|---|---|---|
| Total (0–172) |
PWB (0–28) |
SWB (0–28) |
EWB (0–24) |
FWB (0–28) |
MS (0–64) |
|
| Sample cohort | ||||||
| Week 0 (n = 11)a | 127.0 (21.0) | 20.5 (5.3) | 23.0 (2.9) | 15.5 (5.1) | 17.8 (5.8) | 50.1 (7.8) |
| Week 9 (n = 11) | 130.1 (33.7) | 22.9 (5.2) | 21.3 (6.9) | 16.4 (7.2) | 18.8 (7.7) | 50.7 (11.0) |
| Week 12, no progression (n = 10)b | 130.8 (25.4) | 22.9 (5.5) | 21.5 (3.3) | 17.6 (4.8) | 20.6 (5.3) | 53.6 (7.0) |
| Week 12, progression (n = 9)c | 129.2 (19.3) | 21.8 (5.1) | 22.4 (4.7) | 16.3 (4.1) | 19.4 (4.2) | 49.2 (11.0) |
FACT-G Functional Assessment of Cancer Therapy-General, FACT-M Functional Assessment of Cancer Therapy-Melanoma Module, PWB physical well-being, SWB social well-being, EWB emotional well-being, FWB functional well-being, MS, Melanoma subscale. Higher scores on both the FACT-G and FACT-M indicate a better patient quality of life
n = 11 for the FACT-M scores for the week 0 sample cohort rather than n = 10 because one participant from this cohort completed the FACT-M survey but declined to participate in the semistructured interview
n = 9 for the melanoma-specific well-being score for the week 12 no progression sample cohort because one participant from this cohort did not provide answers to the melanoma-specific well-being items in the FACT-M survey
n = 9 for the FACT-M scores for the week 12 progression sample cohort rather than n = 10 because one participant from this cohort participated in the semistructured interview but declined to complete the FACT-M survey